These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 4004989)
41. Molecular interactions in human atherosclerotic plaques. Smith EB Am J Pathol; 1977 Mar; 86(3):665-74. PubMed ID: 65917 [TBL] [Abstract][Full Text] [Related]
42. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]. Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741 [TBL] [Abstract][Full Text] [Related]
43. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]. Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582 [TBL] [Abstract][Full Text] [Related]
44. Fibronectin distribution in human aortic intima and atherosclerotic lesions: concentration of soluble and collagenase-releasable fractions. Smith EB; Ashall C Biochim Biophys Acta; 1986 Jan; 880(1):10-5. PubMed ID: 3002486 [TBL] [Abstract][Full Text] [Related]
46. [Possibilities of early diagnosis of thromboembolic complications in myocardial infarct by means of biochemical methods]. Andreenko GV; Bessolitsyna LA; Sargin KE Kardiologiia; 1977 Jan; 17(1):98-103. PubMed ID: 140260 [TBL] [Abstract][Full Text] [Related]
47. Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. Vaughan DE; Goldhaber SZ; Kim J; Loscalzo J Circulation; 1987 Jun; 75(6):1200-3. PubMed ID: 3105914 [TBL] [Abstract][Full Text] [Related]
49. Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction. Engel AM; Finkelstein AE Haemostasis; 1981; 10(4):203-14. PubMed ID: 7250787 [TBL] [Abstract][Full Text] [Related]
50. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction. Gram J Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835 [TBL] [Abstract][Full Text] [Related]
51. The release of an immobilized lipoprotein fraction from atherosclerotic lesions by incubation with plasmin. Smith EB; Massie IB; Alexander KM Atherosclerosis; 1976 Oct; 25(1):71-84. PubMed ID: 186079 [TBL] [Abstract][Full Text] [Related]
53. Alterations in the fibrinolytic system components during acute myocardial infarction. Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123 [TBL] [Abstract][Full Text] [Related]
54. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. Eisenberg PR; Sobel BE; Jaffe AS Circulation; 1988 Sep; 78(3):592-7. PubMed ID: 3136954 [TBL] [Abstract][Full Text] [Related]
56. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases. Collatos C; Barton MH; Prasse KW; Moore JN J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947 [TBL] [Abstract][Full Text] [Related]
57. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy. Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754 [TBL] [Abstract][Full Text] [Related]
58. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376 [TBL] [Abstract][Full Text] [Related]
59. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
60. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nakamura Y; Chida Y; Tomura S Nephron; 1991; 58(2):201-4. PubMed ID: 1830934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]